PTC Therapeutics (PTCT) Insider Trading & Ownership $40.39 -0.08 (-0.20%) (As of 11/4/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends PTC Therapeutics (NASDAQ:PTCT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.50%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$198,737.00Number OfInsiders Selling(Last 12 Months)10Amount OfInsider Selling(Last 12 Months)$1.79 M Get PTCT Insider Trade Alerts Want to know when executives and insiders are buying or selling PTC Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address PTCT Insider Buying and Selling by Quarter Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW PTC Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/16/2024Pierre GravierCFOSell2,269$34.02$77,191.38 5/22/2024Jerome B ZeldisDirectorSell20,000$38.24$764,800.00 5/7/2024Lee Scott GoldenEVPSell175$32.82$5,743.50 4/19/2024Matthew B KleinCEOSell3,361$24.89$83,655.29 4/17/2024Eric PauwelsCEOSell787$25.14$19,785.18 4/2/2024Lee Scott GoldenEVPSell526$28.37$14,922.62 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 1/30/2024Christine Marie UtterCAOSell318$27.25$8,665.50 1/30/2024Mark Elliott BouldingVPSell794$27.25$21,636.50 1/30/2024Neil Gregory AlmsteadInsiderSell618$27.25$16,840.50 1/22/2024Allan Steven JacobsonDirectorSell10,000$27.38$273,800.00 1/8/2024Christine Marie UtterCAOSell1,188$28.64$34,024.32 1/8/2024Eric PauwelsInsiderSell1,569$28.64$44,936.16 1/8/2024Mark Elliott BouldingVPSell1,457$28.64$41,728.48 1/8/2024Matthew B KleinCEOSell2,237$28.64$64,067.68 1/8/2024Michael SchmertzlerDirectorSell1,500$27.81$41,715.00 1/5/2024Matthew B KleinCEOSell10,107$27.15$274,405.05 12/12/2023Pierre GravierCFOBuy7,700$25.81$198,737.00 (Data available from 1/1/2013 forward) PTCT Insider Trading Activity - Frequently Asked Questions Who is on PTC Therapeutics's Insider Roster? The list of insiders at PTC Therapeutics includes Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Jerome B Zeldis, Lee Scott Golden, Mark Elliott Boulding, Matthew B Klein, Michael Schmertzler, Neil Gregory Almstead, Pierre Gravier, Stephanie Okey, and Stuart Walter Peltz. Learn more on insiders at PTCT. What percentage of PTC Therapeutics stock is owned by insiders? 5.50% of PTC Therapeutics stock is owned by insiders. Learn more on PTCT's insider holdings. Which PTC Therapeutics insiders have been buying company stock? The following insider purchased PTCT shares in the last 24 months: Pierre Gravier ($198,737.00). How much insider buying is happening at PTC Therapeutics? Insiders have purchased a total of 7,700 PTCT shares in the last 24 months for a total of $198,737.00 bought. Which PTC Therapeutics insiders have been selling company stock? The following insiders have sold PTCT shares in the last 24 months: Alethia Young ($465,006.76), Allan Steven Jacobson ($1,540,640.00), Christine Marie Utter ($1,789,819.91), David P Southwell ($1,162,900.42), Emily Luisa Hill ($418,274.36), Emma Reeve ($238,256.40), Eric Pauwels ($136,960.42), Jerome B Zeldis ($764,800.00), Lee Scott Golden ($20,666.12), Mark Elliott Boulding ($3,341,241.50), Matthew B Klein ($615,145.76), Michael Schmertzler ($41,715.00), Neil Gregory Almstead ($63,658.94), Pierre Gravier ($77,191.38), and Stuart Walter Peltz ($246,486.20). How much insider selling is happening at PTC Therapeutics? Insiders have sold a total of 243,118 PTC Therapeutics shares in the last 24 months for a total of $10,922,763.17 sold. PTC Therapeutics Key ExecutivesDr. Matthew B. Klein F.A.C.S. (Age 51)M.D., M.S., CEO & Director Compensation: $995.4kDr. Stuart W. Peltz Ph.D. (Age 64)Co-Founder, Senior Consultant & Member of Scientific Advisory Board Compensation: $1.54MDr. Allan Steven Jacobson Ph.D. (Age 78)Co-Founder, Chairman of Scientific Advisory Board & Independent Director Compensation: $145kDr. Neil Almstead Ph.D. (Age 57)Chief Technical Operations Officer Compensation: $829.97kMr. Eric Pauwels (Age 63)Chief Business Officer Compensation: $847.67kMr. Pierre Gravier M.S. (Age 38)Chief Financial Officer 1 recent tradesMs. Christine Utter (Age 46)Senior VP, Chief Accounting Officer & Head of People Services Compensation: $595.54kAlex KaneInvestor Relations OfficerMr. Mark Elliott Boulding (Age 63)Executive VP & Chief Legal Officer Compensation: $824.09kMs. Jane BajVice President of Corporate Communications More Insider Trading Tools from MarketBeat Related Companies IONS Insider Selling EBS Insider Selling SAGE Insider Selling INSM Insider Selling PCVX Insider Selling SRPT Insider Selling CTLT Insider Selling RVMD Insider Selling ITCI Insider Selling ROIV Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Big Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock2 Stocks to Buy and 1 to Sell - Smart Moves for Investors3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside This page (NASDAQ:PTCT) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTCT Stock Alerts